Cannon Global Investment Management LLC Purchases Shares of 47,500 aTyr Pharma, Inc. (NASDAQ:ATYR)

Cannon Global Investment Management LLC acquired a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 47,500 shares of the company's stock, valued at approximately $143,000. Cannon Global Investment Management LLC owned 0.05% of aTyr Pharma as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $144,000. Victory Capital Management Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $39,000. Farther Finance Advisors LLC acquired a new position in aTyr Pharma during the fourth quarter valued at approximately $88,000. Finally, American Century Companies Inc. bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $319,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ATYR. Wells Fargo & Company increased their price target on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, June 20th. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $20.20.

aTyr Pharma Stock Down 0.5%

ATYR traded down $0.03 during trading on Friday, hitting $5.25. The company had a trading volume of 2,380,688 shares, compared to its average volume of 1,240,670. The company has a market capitalization of $467.61 million, a PE ratio of -6.49 and a beta of 0.89. aTyr Pharma, Inc. has a one year low of $1.48 and a one year high of $5.98. The firm's 50-day moving average price is $4.38 and its 200 day moving average price is $3.80. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.